Success Story

ONAMI portfolio company Neuramedica raises $1M

NeuraMedica hopes to get FDA clearance to bring its Dural Clip technology for spinal surgery to market by the end of 2021.

Forunded in 2014, the company’s first grant was from Oregon Health & Science University/Oregon Clinical and Translational Research Institute, and it has since raised $3.6 million. It has multiple patents, has completed animal testing and hopes to get FDA clearance this year and bring its product to market by the end of 2021, according to a fact sheet.

NeuraMedica is headed by co-founder and CEO Rachel Dreilinger, a biomedical engineer. Learn more about Rachel as a successful entrepreneur as featured in the National Instutes of Health "Success Stories" article here.

The NeuraMedica Dural Clip represents “an innovative advancement in durotomy closure,” according to the company’s website. “The dura mater is a membrane that covers and protects the brain and spinal cord and contains the circulating cerebro-spinal fluid.”

When the membrane is either accidentally or deliberately severed, the fluid spills out and the cut must be repaired quickly, typically with a fine suture under magnification. This is a “tedious and time-consuming process,” according to NeuraMedica.

The clip is designed to close the dura mater. It is bioabsorbable and applied with a custom, disposable applicator. Other features: It does not lacerate the dura, reducing the potential for leaks; the system will close the dura faster than a suture; and it is simple to use and reduces the need for secondary closure with grafts or tissue adhesives.

Learn more: